Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menitorix + Infanrix Penta versus NeisVac-C + Infanrix Hexa in infant primary and booster vaccination
2005-005421-59Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease comparing Menitorix + Infanrix Penta with NeisVac-C + Infanrix Hexa (2 arms). Started Jan 2006; status: completed.
02
Drugs
Hib-MenC-TTMeningococcal group C polysaccharide conjugate vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccinepertussis filamentous haemagglutinin
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2005-005421-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005421-59.